Invivyd Inc. has announced positive initial data from its ongoing Phase 1 clinical trial of VYD222, a monoclonal antibody candidate in development for the prevention of symptomatic COVID-19 in immunocompromised people. The early serum samples from the first cohort showed strong neutralization activity against Omicron XBB.1.5, one of the dominant SARS-CoV-2 variants circulating globally. Higher VYD222 dose levels tested in the Phase 1 clinical trial are designed to provide greater protection from any potential loss of neutralization activity as SARS-CoV-2 evolves over time.
Invivyd's investigational mAb adintrevimab is also being used to inform VYD222 dose selection for its pivotal clinical trial. Invivyd plans to utilize initial data from the Phase 1 VYD222 clinical trial to help support the anticipated rapid transition to a pivotal clinical trial and present additional results at an upcoming medical meeting.
Biopharmaceutical company, Invivyd Inc., has reported that their monoclonal antibody candidate, VY